Adamo / Lay Carbohydrate-Based Therapeutics

1. Auflage 2023
ISBN: 978-3-527-83131-9
Verlag: Wiley-VCH
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 416 Seiten, E-Book

The book covers current progress and opens new frontiers in carbohydrate-based therapeutic applications. It presents a detailed background of the diseases coupled with the subsequent carbohydrate-based therapies. This aspect renders this book unique and will serve as a quick reference practical book of carbohydrate applications. The link between chemistry and design of novel carbohydrate-based medicines is highlighted and broad overview of all the potential applications of carbohydrates is given. Emphasis is laid on concepts used for carbohydrate drug design, structure-activity relationship and impact on health and diseases.

Autoren/Hrsg.

Adamo, Roberto

Lay, Luigi

Inhaltsverzeichnis

PART I
ANTIMICROBIAL CARBOHYDRATE BASED THERAPIES
Antibacterial Vaccines
Antiviral Vaccines
Antifungal Therapies
Anti Influenza Therapeutics
Antiadhesive Carbohydrates and Glycomimetics
 
PART II
ANTI CANCER CARBOHYDRATE-BASED THERAPIES
 
Cancer Vaccines and Immunotherapy
Carbohydrate Tools in Cancer Biology
Carbohydrates and Glycoconjugates in Autophagy
Lectin Ligands to Target Cancer
 
PART III
CARBOHYDRATE-BASED THERAPIES IN METABOLIC, NEURONAL AND IMMUNE DISORDERS
Carbohydrate-Based Therapeutics for Lysosomal Disorders
Carbohydrate-Based Therapeutics for Neurodegenerative Diseases
Carbohydrate-Based Antithrombotics
Glycans and Blood Types
Carbohydrate-Based Therapeutics for Autoimmune Diseases
N-Glycosylation of Antibodies and Immunity
Type 1 Diabetes
 
PART IV
NEW FRONTIERS IN CARBOHYDRATE-BASED THERAPIES
Carbohydrates for Tissue Engineering
Antiangiogenic and Regenerative Medicine
Carbohydrate-Based Therapeutics for Bowel Diseases

Über Autor(innen)

Roberto Adamo joined Novartis Vaccines in 2007 where he was later appointed Head of the Carbohydrate Chemistry Laboratory, and Leader of the Conjugation & Synthesis Platform. After the GSK acquisition of the company he became Preclinical Representative Leader of the Conjugation Platform. He is currently Technology and Project Leader at GSK, Italy. His research focuses on the synthesis of glycans, glycoconjugates and glyconanoparticles to be used for carbohydrate-based therapeutics. He has over 70 publications in the field including a book. He is the Associate editor of the Glycoconjugate Journal.
 
Luigi Lay is full professor at the Department of Chemistry of the University of Milan. His research interests are focused on carbohydrate chemistry and the use of synthetic glycans to investigate their biological properties. He is author of 86 publications in the field and some book chapters.